Potent and Selective Inhibitors of Glutathione S-Transferase Omega 1 That Impair Cancer Drug Resistance

详细信息    查看全文

• 作者：Katsunori Tsuboi ; Daniel A. Bachovchin ; Anna E. Speers ; Timothy P. Spicer ; Virneliz Fernandez-Vega ; Peter Hodder ; Hugh Rosen ; Benjamin F. Cravatt
• 刊名：Journal of the American Chemical Society
• 出版年：2011
• 出版时间：October 19, 2011
• 年：2011
• 卷：133
• 期：41
• 页码：16605-16616
• 全文大小：1306K
• 年卷期：v.133,no.41(October 19, 2011)
• ISSN：1520-5126

文摘

Glutathione S-transferases (GSTs) are a superfamily of enzymes that conjugate glutathione to a wide variety of both exogenous and endogenous compounds for biotransformation and/or removal. Glutathione S-tranferase omega 1 (GSTO1) is highly expressed in human cancer cells, where it has been suggested to play a role in detoxification of chemotherapeutic agents. Selective inhibitors of GSTO1 are, however, required to test the role that this enzyme plays in cancer and other (patho)physiological processes. With this goal in mind, we performed a fluorescence polarization activity-based protein profiling (fluopol-ABPP) high-throughput screen (HTS) with GSTO1 and the Molecular Libraries Small Molecule Repository (MLSMR) 300K+ compound library. This screen identified a class of selective and irreversible 伪-chloroacetamide inhibitors of GSTO1, which were optimized to generate an agent KT53 that inactivates GSTO1 with excellent in vitro (IC₅₀ = 21 nM) and in situ (IC₅₀ = 35 nM) potency. Cancer cells treated with KT53 show heightened sensitivity to the cytotoxic effects of cisplatin, supporting a role for GSTO1 in chemotherapy resistance.